Global biosimilars development should be streamlined to take into account the latest science and years of market experience, the International Generic and Biosimilar medicines Association has urged in a new policy paper that advocates “changing the biosimilar development paradigm.”
In particular, the global off-patent body has pointed to the limited value of comparative efficacy clinical data, urging a greater emphasis on analytical data over clinical studies but acknowledging that this will require renewed